Sodium valproate blocks the transforming growth factor (TGF)-β1 autocrine loop and attenuates the TGF-β1-induced collagen synthesis in a human hepatic stellate cell line

International Journal of Molecular Medicine

Volumn 28, Issue 6, 2011, Pages 919-925

  Watanabe, Toshifumi ^a,b   Tajima, Hidehiro ^a   Hironori, Hayashi ^a   Nakagawara, Hisatoshi ^a   Ohnishi, Ichiro ^a   Takamura, Hiroyuki ^a   Ninomiya, Itasu ^a   Kitagawa, Hirohisa ^a   Fushida, Sachio ^a   Tani, Takashi ^a   Fujimura, Takashi ^a   Tetsuo, Ota ^a   Wakayama, Tomohiko ^a   Iseki, Shoichi ^a   Harada, Shinichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b TOYAMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Hepatic stellate cell; Liver fibrosis; Transforming growth factor ; Valproate

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA1; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; ATTENUATION; AUTOCRINE EFFECT; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL;

AUTOCRINE COMMUNICATION; CELL LINE; CELL PROLIFERATION; COLLAGEN TYPE I; HEPATIC STELLATE CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER; LIVER CIRRHOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; VALPROIC ACID;

EID: 80053485017     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.768     Document Type: Article

References (28)

1. Niki T, Rombouts K, De Bleser P, et al: A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29: 858-867, 1999. (Pubitemid 29109602)
2. Bülow R, Fitzner B, Sparmann G, Emmrich J, Liebe S and Jaster R: Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol 74: 1747-1757, 2007. (Pubitemid 350088679)
3. Brenner DA: Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 120: 361-368, 2009.
4. George J, Wang SS, Sevcsik AM, Sanicola M, Cate RL, Koteliansky VE and Bissell DM: Transforming growth factor-β initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol 156: 115-124, 2000. (Pubitemid 30644444)
5. Arias M, Lahme B, Van de Leur E, Gressner AM and Weiskirchen R: Adenoviral delivery of an antisense RNA complementary to the 3′ coding sequence of transforming growth factor-β1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ 13: 265-273, 2002. (Pubitemid 34755379)
6. Khan AU and Krishnamurthy S: Histone modifications as key regulators of transcription. Front Biosci 10: 866-872, 2005.
7. Fuks F: DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 15: 490-495, 2005.
8. Gavin DP, Kartan S, Chase K, Jayaraman S and Sharma RP: Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J Psychiatr Res 43: 870-876, 2009.
9. Yamaguchi J, Sasaki M, Sato Y, et al: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 101: 355-362, 2010.
10. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H and Moriwaki H: Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 285: 210-217, 2009.
11. Catalano MG, Poli R, Pugliese M, Fortunati N and Boccuzzi G: Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14: 839-845, 2007. (Pubitemid 350074071)
12. Haefner M, Bluethner T, Niederhagen M, et al: Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 14: 3681-3692, 2008.
13. Rombouts K, Niki T, Greenwel P, et al: Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-β1-Induced fibrogenesis in skin fibroblasts. Exp Cell Res 278: 184-197, 2002. (Pubitemid 35002103)
14. Lee TM, Lin MS and Chang NC: Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol 293: H968-H977, 2007.
15. Rishikof DC, Ricupero DA, Liu H and Goldstein RH: Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem 91: 740-748, 2004.
16. Nakanuma S, Tajima H, Ohta T, et al: Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2. Int J Oncol 36: 793-800, 2010.
17. Yagi Y, Fushida S, Ohta T, et al: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 29: 149-159, 2010.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ÄÄCT method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
19. Xu W, Chen H, Du K, et al: A transcriptional switch mediated by cofactor methylation. Science 294: 2507-2511, 2001. (Pubitemid 34027283)
20. Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086, 2004. (Pubitemid 38176913)
21. So CC and Wong KF: Valproate-associated dysmyelopoiesis in elderly patients. Am J Clin Pathol 118: 225-228, 2002.
22. Solanki RK, Singh P, Khandelwal R and Midha A: Efficacy and tolerability of injectable sodium valproate in patients with mania. Indian J Psychiatry 48: 118-120, 2006.
23. Chang YZ, Yang L and Yang CQ: Migration of hepatic stellate cells in fibrotic microenvironment of diseased liver model. Hepatobiliary Pancreat Dis Int 7: 401-405, 2008.
24. Shirai Y, Kawata S, Tamura S, et al: Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73: 2275-2279, 1994. (Pubitemid 24129108)
25. Atmaca A, Al-Batran SE, Maurer A, et al: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97: 177-182, 2007. (Pubitemid 47057472)
26. Mousavi SA, Fønhus MS and Berg T: Up-regulation of uPARAP/Endo180 during culture activation of rat hepatic stellate cells and its presence in hepatic stellate cell lines from different species. BMC Cell Biol 10: 39-49, 2009.
27. Yoshikawa M, Hishikawa K, Marumo T and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007. (Pubitemid 46053422)
28. Ghosh AK, Mori Y, Dowling E and Varga J: Trichostatin A blocks TGF-β-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun 354: 420-426, 2007. (Pubitemid 46161342)